A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition
Abstract
Background: In 2023 and 2024, research into semaglutide (SEMA), an antiobesity and antidiabetic medication, indicated potential benefits beyond its approved uses, particularly in preventing Alzheimer's disease (AD). This highlights the link between obesity and AD development.
Objectives: This systematic review and meta-analysis evaluates clinical studies assessing SEMA's effects on subcutaneous and visceral adipose tissue (SAT/VAT) measures, brain function, cognitive performance through cognitive tasks, and the incidence of cognitive disorders.
Methods: We searched databases for studies evaluating these outcomes pre- and post-SEMA treatment, with the last update on November 9, 2024. We included studies regardless of treatment duration, estimating pre-post standardized mean differences (SMD) for one-group and two-group designs using a random-effects model.
Results: We included 23 studies: 18 on SAT/VAT outcomes and five on brain function and cognitive impairment. Meta-analyses revealed significant VAT reductions but no significant impact on SAT. SEMA demonstrated neuroprotective effects, lowering the risk of AD compared to various treatments.
Conclusion: Our systematic appraisal highlighted high heterogeneity across available original investigations. Within this context, meta-analytic findings suggest that SEMA may be able to promote VAT loss and support cognitive preservation. Sequencing these effects, VAT loss and cognitive preservation, is an important question open for…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.